Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 724-733

  Williams, Jon I ^a   Holroyd, Kenneth J ^a   McLane, Michael P ^a   Chen, Qiming ^a   Zasloff, Michael ^a   Weitman, Steven ^b   Gonzalez, Cristina M ^b   Jundt, Carita H ^b   Marty, Jennifer ^b   Stringer, Stephanie D ^b   Von Hoff, Daniel D ^b  

^a Genaera Corporation   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM; SQUALAMINE; VASCULAR CELL ADHESION MOLECULE 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ACTINS; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELLS, CULTURED; CHOLESTANOLS; CISPLATIN; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PLATINUM COMPOUNDS; TIME FACTORS; TUMOR CELLS, CULTURED; UMBILICAL VEINS;

EID: 0034906455     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Epidemiology of cancer: Global patterns and trends
2. Lung cancer: Therapeutic modalities and cytoprotection
3. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
4. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial
5. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer
6. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, Adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study
7. Treatment of advanced non-small cell lung cancer (NSCLC): The "Umbria" cooperative study
8. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer
9. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial
10. Platinum/etoposide therapy in non-small cell lung cancer
11. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group
12. Lung cancer: Review of the ECOG experience
13. The clinical development of paclitaxel and the paclitaxel/carboplatin combination
14. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer
15. Role of taxanes in lung-cancer chemotherapy
16. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
17. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
18. Postoperative treatment of nonmetastatic visible residual neuroblastoma: A Pediatric Oncology Group study
19. Cyclophosphamide/doxorubicin vs. Cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: A Pediatric Oncology Group randomized Phase II study
20. High-dose therapy with hematopoietic rescue for children with solid tumors
21. Current aspects of biology, risk assessment, and treatment of neuroblastoma
22. Vascular attack as a therapeutic strategy for cancer
23. Molecular insights into cancer invasion: Strategies for prevention and intervention
24. Translational research: Walking the bridge between idea and cure-seventeenth Bruce F. Cain memorial award lecture
25. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
26. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
27. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
28. A randomized Phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
29. Angiostatic treatment of neuroblastoma
30. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature
31. Squalamine a new angiostatic steroid
32. Potential of the aminosterol, squalamine, in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma
33. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization
34. Evaluation of the angiostatic steroid squalamine as adjunctive chemotherapy for the MX-I breast cancer in a mouse model
35. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with and without overexpression of HER-2/neu oncogene
36. 3 expression by squalamine obliterates advanced human prostate cancer (HPC): Synergism with VEGF
37. Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents
38. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S
39. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
40. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model
41. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and Paraplatin regimens against the MV-522 human lung cancer xenograft
42. Vascular-endothelial cadherin (CD144)-but not PECAM-1 (CD31)-based cell-to-cell contacts convey the maintenance of a quiescent endothelial monolayer
43. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo
44. A randomized Phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
45. A randomized Phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
46. An economic analysis of Southwest Oncology Group trial S9509: Cisplatin/vinorelbine versus carboplatin/paclitaxel for advanced non-small cell lung cancer
47. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung
48. Carboplatin versus cisplatin in solid tumors: An analysis of the literature
49. Directed actin polymerization is the driving force for epithelial cell-cell adhesion
50. Myosin light chain kinase-regulated endothelial cell contraction: The relationship between isometric tension, actin polymerization, and myosin phosphorylation
51. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins
52. The proliferative effect of vascular endothelial growth factor requires protein kinase C-α and protein kinase C-ζ
53. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
54. Regulation of TNF-α-induced reorganization of the actin cytoskeleton and cell-cell junctions by Rho, Rac, and cdc42 in human endothelial cells
55. Regulation of cadherin function by Rho and Rac: Modulation by junction maturation and cellular context
56. Rho family proteins in cell adhesion and cell migration